Future Uncertain for U.S. Drug Makers
With the health care debate on hold for the time being drug makers are facing the uncertainty of the impact that the lack of reform will have on their collective futures. As part of the expectation that a health care bill would pass, pharmaceutical companies agreed to provide the government $80 billion in rebates over […]
